跳至主要内容
临床试验/NCT05843552
NCT05843552招募中不适用

Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease

University of Minnesota1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2023年8月14日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
30
试验地点
1
主要终点
EVs quantity

研究概览

简要总结

This is an observational study intended to generate preliminary data to understand how lysosomal dysfunction can affect the biogenesis of extracellular vesicles, its content and function. The primary objective of the proposed project is to decipher how extracellular vesicle (EV) biogenesis and its role in intercellular communication can be impaired as a consequence of defects in lysosomal function. Collectively these defects in EV biogenesis and function can contribute to the neuroinflammation observed in lysosomal storage diseases. Since EVs can cross the blood-brain barrier, their characterization may be valuable in identifying novel biomarkers. In the presence of a GBA1 mutation, the decrease in GCase activity will lower overall lysosome function and increase the secretion of EVs. Further, there will be differences in EV size, its cargo including lipids, RNA and proteins and their aggregates. In comparison to healthy controls, EVs isolated from patients with Gaucher disease (GD) and GBA1 carriers is hypothesized to show significant differences in terms of its characteristics and content, which can contribute to our understanding of the link between lysosomes and neurological disease.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age between 18-80yrs
  • Restricted to participants who are untreated, obligate carriers and healthy controls.
  • Participants with GD should have confirmed GD diagnosis, mutation confirmed for carriers and healthy controls confirmed to have no GBA1 mutation by gene sequencing.

排除标准

  • Exclude participants who have any hematological malignancy or other uncontrolled comorbid conditions.
  • Exclude participants who are currently on therapy for their GD
  • Exclude participants who have any hematological malignancy or other uncontrolled comorbid conditions.

研究组 & 干预措施

patients with GD

干预措施: no intervention (Other)

obligate carriers

干预措施: no intervention (Other)

healthy volunteers

干预措施: no intervention (Other)

结局指标

主要结局

EVs quantity

时间窗: baseline

Examine EV quantities isolated from plasma samples collected from patients with GD and carriers and compare to healthy individuals.

EVs size

时间窗: baseline

Examine EV sizes isolated from plasma samples collected from patients with GD and carriers and compare to healthy individuals.

EVs content

时间窗: baseline

Examine contents in vesicles isolated from plasma samples collected from patients with GD and carriers and compare to healthy individuals.

EVs quantity

时间窗: 3months

Examine EV quantities isolated from plasma samples collected from patients with GD and carriers and compare to healthy individuals.

EVs size

时间窗: 3months

Examine EV sizes isolated from plasma samples collected from patients with GD and carriers and compare to healthy individuals.

EVs content

时间窗: 3months

Examine contents in vesicles isolated from plasma samples collected from patients with GD and carriers and compare to healthy individuals.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验